EP4175958A4 - Compounds having anticancer activity - Google Patents
Compounds having anticancer activityInfo
- Publication number
- EP4175958A4 EP4175958A4 EP21832527.2A EP21832527A EP4175958A4 EP 4175958 A4 EP4175958 A4 EP 4175958A4 EP 21832527 A EP21832527 A EP 21832527A EP 4175958 A4 EP4175958 A4 EP 4175958A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compounds
- anticancer activity
- anticancer
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047612P | 2020-07-02 | 2020-07-02 | |
| PCT/US2021/040171 WO2022006447A1 (en) | 2020-07-02 | 2021-07-01 | Compounds having anticancer activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4175958A1 EP4175958A1 (en) | 2023-05-10 |
| EP4175958A4 true EP4175958A4 (en) | 2024-07-17 |
Family
ID=79314944
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21832527.2A Pending EP4175958A4 (en) | 2020-07-02 | 2021-07-01 | Compounds having anticancer activity |
| EP21832744.3A Pending EP4175953A4 (en) | 2020-07-02 | 2021-07-01 | Compounds having antibacterial activity |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21832744.3A Pending EP4175953A4 (en) | 2020-07-02 | 2021-07-01 | Compounds having antibacterial activity |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20230242540A1 (en) |
| EP (2) | EP4175958A4 (en) |
| JP (2) | JP2023532128A (en) |
| CN (2) | CN116234808A (en) |
| AU (2) | AU2021301264A1 (en) |
| CA (2) | CA3183776A1 (en) |
| WO (2) | WO2022006432A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024077235A2 (en) * | 2022-10-07 | 2024-04-11 | The Trustees Of Princeton University | Dihydrofolate reductase inhibitors for anti-biotic resistant infections |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140329840A1 (en) * | 2013-05-06 | 2014-11-06 | Georgia Tech Research Corporation | Molecules with potent dhfr binding affinity and antibacterial activity |
| US20190201401A1 (en) * | 2017-08-01 | 2019-07-04 | The Trustees Of Princeton University | Compounds having antibacterial activity and methods of use |
| WO2019212933A1 (en) * | 2018-04-30 | 2019-11-07 | Duke University | Compositions and methods for the treatment of senescent tumor cells |
| WO2021035045A1 (en) * | 2019-08-20 | 2021-02-25 | City Of Hope | Mettl16 inhibitors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4118561A (en) * | 1977-04-06 | 1978-10-03 | American Home Products Corporation | 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines |
| US6740657B2 (en) * | 2001-02-23 | 2004-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists |
| US7253177B2 (en) * | 2004-10-22 | 2007-08-07 | United States Of America As Represented By The Secretary Of The Army | Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives |
| US9133203B2 (en) * | 2013-06-20 | 2015-09-15 | Oregon Health & Science University | Pyrroloquinazoline compounds |
| ES2952367T3 (en) * | 2014-05-11 | 2023-10-31 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Therapeutic conjugates based on PAR-1 and uses thereof |
-
2021
- 2021-07-01 JP JP2022581398A patent/JP2023532128A/en active Pending
- 2021-07-01 US US18/013,302 patent/US20230242540A1/en active Pending
- 2021-07-01 CN CN202180047426.0A patent/CN116234808A/en active Pending
- 2021-07-01 CA CA3183776A patent/CA3183776A1/en active Pending
- 2021-07-01 US US18/014,032 patent/US20230295164A1/en active Pending
- 2021-07-01 WO PCT/US2021/040143 patent/WO2022006432A1/en active Application Filing
- 2021-07-01 JP JP2023524493A patent/JP2023535527A/en active Pending
- 2021-07-01 CA CA3183770A patent/CA3183770A1/en active Pending
- 2021-07-01 AU AU2021301264A patent/AU2021301264A1/en active Pending
- 2021-07-01 CN CN202180047260.2A patent/CN115867354A/en active Pending
- 2021-07-01 WO PCT/US2021/040171 patent/WO2022006447A1/en active Application Filing
- 2021-07-01 EP EP21832527.2A patent/EP4175958A4/en active Pending
- 2021-07-01 AU AU2021299504A patent/AU2021299504A1/en active Pending
- 2021-07-01 EP EP21832744.3A patent/EP4175953A4/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140329840A1 (en) * | 2013-05-06 | 2014-11-06 | Georgia Tech Research Corporation | Molecules with potent dhfr binding affinity and antibacterial activity |
| US20190201401A1 (en) * | 2017-08-01 | 2019-07-04 | The Trustees Of Princeton University | Compounds having antibacterial activity and methods of use |
| WO2019212933A1 (en) * | 2018-04-30 | 2019-11-07 | Duke University | Compositions and methods for the treatment of senescent tumor cells |
| WO2021035045A1 (en) * | 2019-08-20 | 2021-02-25 | City Of Hope | Mettl16 inhibitors and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| CHUMEI HUANG: "MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells", THERANOSTICS, vol. 8, no. 11, 1 January 2018 (2018-01-01), AU, pages 3074 - 3086, XP093169040, ISSN: 1838-7640, DOI: 10.7150/thno.24281 * |
| MARTIN JAMES K ET AL: "A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance", CELL, ELSEVIER, AMSTERDAM NL, vol. 181, no. 7, 3 June 2020 (2020-06-03), pages 1518, XP086202864, ISSN: 0092-8674, [retrieved on 20200603], DOI: 10.1016/J.CELL.2020.05.005 * |
| See also references of WO2022006447A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230295164A1 (en) | 2023-09-21 |
| EP4175953A1 (en) | 2023-05-10 |
| CA3183776A1 (en) | 2022-01-06 |
| JP2023535527A (en) | 2023-08-17 |
| EP4175958A1 (en) | 2023-05-10 |
| WO2022006447A1 (en) | 2022-01-06 |
| CN116234808A (en) | 2023-06-06 |
| AU2021299504A1 (en) | 2023-02-02 |
| AU2021301264A1 (en) | 2023-02-02 |
| US20230242540A1 (en) | 2023-08-03 |
| CA3183770A1 (en) | 2022-01-06 |
| JP2023532128A (en) | 2023-07-26 |
| EP4175953A4 (en) | 2024-08-14 |
| CN115867354A (en) | 2023-03-28 |
| WO2022006432A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309099A (en) | Anticancer compounds | |
| SG11202009088VA (en) | Compound with anticancer activity | |
| EP4175958A4 (en) | Compounds having anticancer activity | |
| IL290244A (en) | Anticancer agents | |
| GB202104274D0 (en) | Anticancer compounds | |
| GB202004321D0 (en) | Anticancer compounds | |
| GB202304418D0 (en) | Anticancer compounds | |
| GB202204285D0 (en) | Anticancer compounds | |
| GB201904544D0 (en) | Anticancer compounds | |
| GB201902705D0 (en) | Anticancer compounds | |
| EP3990434A4 (en) | Compounds having antimalarial activity | |
| GB201917687D0 (en) | Compounds with antimicrobial activity | |
| IL286700A (en) | Anticancer combination therapy | |
| EP3971180A4 (en) | Compounds inhibiting tdg activity | |
| EP4188553C0 (en) | Compounds | |
| GB202020579D0 (en) | Compounds with antimicrobial activity | |
| EP4188933A4 (en) | Compounds | |
| GB202013558D0 (en) | GRP52 Modularor compounds | |
| GB202012802D0 (en) | Compounds | |
| GB202011924D0 (en) | Compounds | |
| GB202011811D0 (en) | Compounds | |
| GB202011537D0 (en) | Compounds | |
| GB202010862D0 (en) | Compounds | |
| GB202010359D0 (en) | Compounds | |
| GB202009944D0 (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230115 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20240619 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/519 20060101ALI20240613BHEP Ipc: A61P 35/00 20060101ALI20240613BHEP Ipc: C07D 487/02 20060101AFI20240613BHEP |